The Vanguard Group, Inc. has recently announced that it has increased stake in Oncternal Therapeutics Inc. (NASDAQ:ONCT) by 34.38%. After grabbing 2.85 million shares, the institutional investor is now in possession of 0.73 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 5.05% having worth around $2.59 million. Moreover, Renaissance Technologies LLC increased its share by 0.34 million to have a control over 0.98 million shares. And Quantum Private Wealth LLC raised its holdings to 5700.0 shares by acquiring 0.46 million shares or 0.82% of the stake.
Oncternal Therapeutics Inc. (ONCT) concluded trading on 01/11/23 at a closing price of $1.26, with 1.01 million shares of worth about $1.28 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 11.50% during that period and on Wednesday the price saw a gain of about 10.53%. Currently the company’s common shares owned by public are about 54.21M shares, out of which, 51.46M shares are available for trading.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 19 times over the past 12 months. They bought 525,375 shares in 19 of the transactions. In 0 selling transactions, insiders dumped 0 shares.
Vanguard Total Stock Market Index, FCP Medical – BioHealth, and Vanguard Extended Market Index Fu are the top 3 mutual funds which are holding stakes in Oncternal Therapeutics Inc. Vanguard Total Stock Market Index is currently holding 2.16 million shares of worth totaling $1.97 million. The company recently came buying 0.0 shares which brought its stake up to 3.83% of the company’s outstanding shares. Vanguard Extended Market Index Fu, after buying 0.62 million shares, have now control over 1.10% of the stake in the company. It holds 0.0 shares of worth $0.56 million.
However, the stock later moved at a day high price of 1.2900, or with a gain of 10.53%. Stock saw a price change of 21.15% in past 5 days and over the past one month there was a price change of 17.76%. Year-to-date (YTD), ONCT shares are showing a performance of 26.00% which decreased to -41.12% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.69 but also hit the highest price of $2.22 during that period. The average intraday trading volume for Oncternal Therapeutics Inc. shares is 270.70K. The stock is currently trading 29.49% above its 20-day simple moving average (SMA20), while that difference is up 28.59% for SMA50 and it goes to 17.86% higher than SMA200.
The Vanguard Group, Inc. acquired 2.85 million shares of Oncternal Therapeutics Inc. having value of about $2.59 million. Data submitted at the U.S SEC by The Vanguard Group, Inc. revealed that the firm now holds 0.73 million shares in the company valued at close to $917532.0, or have control over 34.38% stake in the company. Oncternal Therapeutics Inc. (NASDAQ: ONCT) currently have 54.21M outstanding shares and institutions hold larger chunk of about 18.90% of that. Holding of mutual funds in the company is about 3.38% while other institutional holders and individual stake holders have control over 8.89% and 10.24% of the stake respectively.
The stock has a current market capitalization of $72.32M and its 3Y-monthly beta is at 1.36. It has posted earnings per share of -$0.80 in the same period. It has Quick Ratio of 9.80 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ONCT, volatility over the week remained 9.10% while standing at 8.59% over the month.
Analysts are in expectations that Oncternal Therapeutics Inc. (ONCT) stock would likely to be making an EPS of -$0.24 in the current quarter, while forecast for next quarter EPS is -$0.24 and it is -$0.85 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.26 which is -$0.21 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.19 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 25.10% while it is estimated to increase by 1.20% in next year. EPS is likely to shrink at an annualized rate of 0.00% for next 5-years, compared to annual growth of 12.20% made by the stock over the past 5-years.
Analysts at 6 brokerage firms have issued recommendations for the Oncternal Therapeutics Inc. (ONCT)’s stock and average of those rates the stock at a “Strong Buy” and assign it a score of 1.70. Out of those 6 Wall Street analysts, 6 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Oppenheimer on April 07, 2021 offering an Outperform rating for the stock and assigned a target price of $14 to it. Coverage by Northland Capital stated Oncternal Therapeutics Inc. (ONCT) stock as an Outperform in their note to investors on February 23, 2021, suggesting a price target of $21 for the stock.